2017 MAP Conference: Unacknowledged Growth Inhibition of MAP by Immunomodulators

by Dr. Robert Greenstein

Dr. Greenstein is a researcher in the Laboratory of Molecular Surgical Research at the VA Medical Center in Bronx, NY. He presents his research explaining why he believes that the primary action of current Crohn’s disease therapies is really Anti-MAP, and hypothesizes that Crohn’s disease may be the tip of the MAP iceberg. The antimycobacterial effect of Vitamin D is also discussed.

Pin It on Pinterest

Share This